New Drugs Aim To Move Needle In Tough-to-Treat Acute Myeloid Leukemia
Executive Summary
Response rates for candidates from Stemline, Seattle Genetics and Karyopharm look highly encouraging, but the real test in AML will be survival, as the field is still in the shadow of Pfizer's failed Mylotarg.
You may also be interested in...
Novartis' Rydapt: Two Indications, Two Prices
Rydapt was approved by the US FDA for the one-third of patients with acute myeloid leukemia who test positive for a FLT3 mutation, which is associated with a poorer prognosis, and for advanced systemic mastocytosis.
Karyopharm Absorbs Selinexor AML Blow, Focuses On Other Cancers
Upcoming Phase II in diffuse large B-cell lymphoma offers opportunity for a rebound after single agent selinexor disappoints in SOPRA study of acute myeloid leukemia.
AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces
Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.